Oppenheimer analyst, Hartaj Singh, reiterated a Perform rating on Sarepta Therapeutics (NASDAQ: SRPT) as the company prepares to present the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE